ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 1 filers reported holding ASCENDIS PHARMA A/S in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,559,761 | +3.1% | 16,657 | -1.7% | 2.01% | +10.5% |
| Q2 2023 | $1,512,520 | +32.4% | 16,947 | +59.1% | 1.82% | +15.1% |
| Q1 2023 | $1,142,107 | -58.2% | 10,652 | -52.3% | 1.58% | -39.6% |
| Q4 2022 | $2,729,239 | -9.3% | 22,347 | -23.3% | 2.62% | -9.5% |
| Q3 2022 | $3,010,000 | +42.9% | 29,146 | +28.6% | 2.90% | +26.3% |
| Q2 2022 | $2,106,000 | -52.1% | 22,659 | -39.6% | 2.29% | -25.0% |
| Q1 2022 | $4,401,000 | -23.4% | 37,501 | -12.2% | 3.06% | +10.9% |
| Q4 2021 | $5,746,000 | +55.1% | 42,712 | +83.8% | 2.76% | +67.8% |
| Q3 2021 | $3,705,000 | +62.1% | 23,242 | +33.8% | 1.64% | +56.0% |
| Q2 2021 | $2,285,000 | +5.7% | 17,370 | +3.6% | 1.05% | -17.5% |
| Q1 2021 | $2,161,000 | +6.1% | 16,764 | +37.3% | 1.28% | -17.7% |
| Q4 2020 | $2,037,000 | – | 12,212 | – | 1.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
| RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
| Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
| BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
| Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
| Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
| Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
| Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
| Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
| Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |